Treatment patterns and outcomes for patients with unresectable stage III and metastatic melanoma in the USA.

Treatment patterns and outcomes for patients with unresectable stage III and metastatic melanoma in the USA.

Publication date: Mar 05, 2019

To describe treatment patterns and outcomes of patients with unresectable stage III and metastatic/stage IV melanoma.

An observational retrospective chart review of patients diagnosed with advanced melanoma before 1 November 2015 who initiated a new line of therapy (LOT) from 1 January 2015 to 31 May 2016. Results: Among 487 patients, ipilimumab monotherapy (27.5%) was the most common first line of therapy (1LOT) in 2015, surpassed by nivolumab monotherapy (21.5%) in 2016. Twelve-month survival was ≥80.1%; proportions were highest forpatients treated with nivolumab + ipilimumab (86.6%). All treatments relatively well tolerated in real-world setting and adverse events were consistent with the previously reported safety profiles.

This study provides important insights into real-world advanced melanoma treatment patterns and demonstrates encouraging treatment safety and patient survival data.

Tarhini, A., Atzinger, C., Gupte-Singh, K., Johnson, C., Macahilig, C., and Rao, S. Treatment patterns and outcomes for patients with unresectable stage III and metastatic melanoma in the USA. 21871. 2019 J Comp Eff Res.

Concepts Keywords
Ipilimumab Pembrolizumab
Melanoma Vemurafenib
Metastatic Nivolumab
Monotherapy Ipilimumab
Breakthrough therapy
Melanoma
Antineoplastic drugs
Bristol-Myers Squibb
Clinical medicine
Cancer treatments
Immunotherapy
Advanced melanoma
Melanoma
Melanoma treatment

Semantics

Type Source Name
drug DRUGBANK Nivolumab
drug DRUGBANK Ipilimumab
pathway BSID Melanoma
disease DOID melanoma
disease MESH melanoma

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *